Cancer Liver

Posts Tagged ‘hepatitis c virus’

Duke Cancer Institute researcher Xiao-Fan Wang, PhD, discusses liver cancer research and hepatitis b virus (HBV) and hepatitis c virus (HCV). He is collaborating with researchers in china where there are many more cases of liver cancer than in the United States.

Product Description
Hepatocellular carcinoma, also called malignant hepatoma, is a primary form of liver cancer that originates in the hepatocyte cells of the liver. Hepatocellular carcinoma is the 5th most common type of cancer worldwide with nearly 500,000 new cases diagnosed each year. Approximately 19,000 cases of primary liver cancer are diagnosed each year in the United States and affects males more than females by a ratio of about 3:1.

Major risk factors for hepatocellular carcinoma include cirrhosis of the liver, chronic infection with the Hepatitis B or Hepatitis C virus, exposure to aflatoxins that can contaminate certain crops, hereditary hemochromatosis, and primary biliary cirrhosis.

Unfortunately, the early diagnosis of hepatocellular carcinoma is difficult because most people with early-stage disease do not exhibit clinical symptoms of the disease. By the time symptoms do develop, the disease has already progressed to a more advanced stage. Signs and symptoms of hepatocellular carcinoma may include abdominal pain, enlargement of the liver and spleen, unintentional weight loss, jaundice, and generalized weakness and fatigue.

The treatment options for patients with hepatocellular carcinoma depend upon a variety of factors including the stage of the disease, location of the tumor, and how well or poorly the liver is functioning. In general, the treatment options for hepatocellular carcinoma can be grouped into those treatments that are intended to be curative and those that are intended to be palliative meaning that they do not cure the underlying disease but rather control the symptoms of the disease. The only known curative treatments for hepatocellular carcinoma are surgical resection and liver transplantation. Palliative treatment options include radiofrequency thermal ablation, percutaneous ethanol injection, cryosurgery, hepatic arterial embolization, and systemic chemotherapy.

Learn more by ordering your MediFocus Guidebook on Liver Cancer, the most comprehensive, up-to-date source of information available. You will get answers to your questions, including:

* What are the risk factors of Liver Cancer?
* What standard and alternative treatment options are available?
* Where are the leading doctors, hospitals and medical centers that specialize in Liver Cancer research and treatment?
* What are the results of the latest clinical trials?
* Where are the support groups and additional resources in my area?
* What are the promising new treatments on the horizon?

You won’t find this combination of information anywhere else. Your health matters. Don’t leave it to chance. Arm yourself with the most comprehensive, up-to-date research available by ordering your MediFocus Guidebook today.

Medifocus Guidebook on: Liver Cancer

Product Description
The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care.

Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood.

Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.

Hepatitis and Liver Cancer

Book Description
The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care.

Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood.

Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.

Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C

In this video, Hans Rosling uses liver cancer statistics to show how cancer data from IARC ( International Agency for research on Cancer) can be displayed as moving bubbles in Gapminder World. In this visual way, you can easily compare data for the most common cancers and rapidly understand that each of them have different distributions in the world. Liver cancer is mainly caused by chronic infection by the Hepatitis B virus (and also by the Hepatitis C virus). As this infection is most common in China and other parts of East Asia, as well as in Africa South of the Sahara, it is the countries in these regions that bear the main burden of Liver Cancer in the World (independent of if they have low, middle or high income). Comparing gender differences indicate that higher alcohol consumption in men may explain why the rate of liver cancer in men is twice as high as in women. is.gd – New cases of liver cancer per 100 000 men (with size showing the total number of new cases of liver cancer)